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Ever since in 2013 Steve Horvath showed that the 
chronological age of a healthy individual can be accura-
tely predicted using a DNA methylation (DNAm) based 
predictor [1], and that deviations between the predicted 
and true age can be informative of lifespan and other 
age-related phenotypes [1, 2], there has been a surge of 
follow-up studies deriving different types of more 
specialized epigenetic clocks aimed at measuring dif-
ferent aspects of the aging process. For instance, unlike 
Horvath’s clock, the “Levine clock” [3] was derived 
using biological measures of aging (e.g. measures of 
cognitive decline) and is therefore more tailored to 
measure biological aging in older individuals. Another 
example is a DNAm-based clock called “epiTOC”, 
aimed at approximating the mitotic age of a tissue, and 
which was shown to be more tailored for predicting 
cancer risk [4]. Although Horvath’s clock remains the 
only clock to accurately predict chronological age 
independently of tissue-type (hence also termed the 
“pan-tissue” clock), and to also predict age-acceleration 
in a wide range of different diseases [5], a long-standing 
puzzle has been its failure to predict age-acceleration in 
a disease like Hutchinson Gilford Progeria Syndrome 
(HGPS), a disease which exhibits all the hallmarks of 
age-acceleration [1, 6]. 
In a recent paper published in the journal Aging, 
Horvath and colleagues offer a potential explanation 
and solution to this puzzle [7]. In the context of HGPS, 
a more relevant cell-type in which to measure DNAm 
are fibroblasts, and not immortalized lymphoblastoid 
cell-lines as done previously [1]. Interestingly, Horvath’s 
clock had been previously observed to not be well calib-
rated in fibroblasts, presumably because the associated 
samples had been cultured, while mostly in-vivo 
samples had been used in the training of the clock itself 
[1]. Thus, Horvath and colleagues set out to derive a 
new epigenetic clock for fibroblasts. An immediate 
challenge facing them, however, was the fact that 
construction of an accurate clock requires on the order 
of many hundreds if not thousands of samples, while 
only a 100 fibroblast samples from four different studies 
were available. To overcome this problem, the authors 
used a larger training set consisting of approximately 
900 samples, encompassing other tissues and cell-types, 
including buccal, blood and skin. Using the same 
statistical framework as in  Horvath’s original work,  the  
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authors derived a new epigenetic clock for 
chronological age, consisting of 391 CpGs, called the 
“skin-blood clock’. Using this skin-blood clock, the 
authors applied it to fibroblast samples from the 
Progeria Research Foundation. This clock predicted 
age-acceleration in HGPS patients, despite the fact that 
the median age was only 8 years, a time when the rate 
of normal, i.e. healthy, epigenetic aging is fastest. 
Importantly, the association between epigenetic age-
acceleration and HGPS status increased significantly 
after adjustment for passage number. This is an impor-
tant finding, because, if validated in future larger 
studies, it provides a means of measuring epigenetic age 
in fibroblasts, which are easily isolated from an 
accessible tissue such as skin, and secondly, because it 
may allow ex-vivo monitoring of the success of progeria 
drug treatments. 
The significance of the study however goes well beyond 
its implications for HGPS and other progeria 
syndromes. First, the skin-blood clock could be used for 
quantitative ex-vivo human cell aging assays generally, 
although its usefulness is likely to be restricted to age-
related conditions and diseases where fibroblasts or 
other skin cell subtypes are relevant. Second, the 
authors applied the clock to cord blood, finding that it 
correlates with gestational age. Third, although the skin-
blood clock was derived from significantly less samples 
(~900) than Horvath’s clock (~8000 samples), it was 
found to more accurately predict chronological age, not 
only across fibroblasts and skin, but also across blood, 
buccal and saliva tissue. A potential factor driving this 
improved accuracy in blood could be related to the 
approximate 18-fold increase in genomic coverage 
afforded by using Illumina 450k/850k beadarrays in-
stead of the much older 27k beadarrays that were used 
in the derivation of the pan-tissue clock. Thus, the 
improved accuracy of the skin-blood clock makes it 
more suitable for forensic applications. 
It should be noted that the skin-blood clock is not meant 
to be a replacement for Horvath’s pan-tissue clock. Al-
though the skin-blood clock also predicts chronological 
age in other cell-types like neurons, glia and liver, it 
remains to be seen if the improved accuracy extends to 
the 30 or more tissue-types used in the validation of the 
pan-tissue clock. Moreover, the skin-blood clock is 
likely to still be biased towards a tissue like blood since 
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over 70% of the training samples derived from whole 
blood, cord blood, peripheral blood mononuclear cells 
or from buccal swabs, a tissue which has recently been 
shown to contain a relatively high fraction of leukocytes 
[8]. Thus, looking forward, it would be important to 
design a study which constructs an epigenetic clock 
from a much larger number, say a thousand fibroblast 
samples, which would therefore not constitute a pan-
tissue clock, but which would be more tailored towards 
measuring age-acceleration in HGPS patients. Such an 
improved tailored clock could form the basis for 
evaluating the effectiveness of progeria treatments via 
an ex-vivo assay. As such, the recently published study 
by Horvath and colleagues is highly significant as it 
serves as a roadmap for future clock studies, pointing 
towards the importance of constructing tissue or cell-
type specific epigenetic clocks, to more accurately 
measure biological aging in the given tissue/cell-type, 
and therefore with the potential to be more informative 
of disease-risk or the success of disease interventions in 
the tissue or cell-type of interest. In doing so, studies 
should profile purified samples to avoid confounding by 
cell-type heterogeneity, or, if profiling complex tissues, 
must adjust for it using appropriate statistical 
methodology [8, 9].   
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